Skip to main content

4 Result(s)

within Yamei Wang Remove this filter Biomedicine Remove this filter

and

  1. Article

    Open Access

    Correction to: Pharmacokinetic and Pharmacodynamic Studies of Elacestrant, A Novel Oral Selective Estrogen Receptor Degrader, in Healthy Post-Menopausal Women

    Authors would like to correct the errors in table 2.

    Maureen G. Conlan, Erik F. J. de Vries… in European Journal of Drug Metabolism and Ph… (2020)

    Download PDF (493 KB) View Article

  2. Article

    Open Access

    Pharmacokinetic and Pharmacodynamic Studies of Elacestrant, A Novel Oral Selective Estrogen Receptor Degrader, in Healthy Post-Menopausal Women

    Advanced estrogen receptor-positive (ER+) breast cancer is currently treated with endocrine therapy. Elacestrant is a novel, nonsteroidal, selective estrogen receptor degrader with complex dose-related ER agon...

    Maureen G. Conlan, Erik F. J. de Vries… in European Journal of Drug Metabolism and Ph… (2020)

    Download PDF (996 KB) View Article

  3. Article

    Open Access

    A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using 18F-FES PET/CT imaging

    Elacestrant is an oral selective estrogen receptor (ER) degrader. This phase 1b open-label, non-randomized study (RAD1901-106) was initiated to determine the effect of elacestrant on the availability of ER in ...

    Agnes Jager, Elisabeth G. E. de Vries… in Breast Cancer Research (2020)

    Download PDF (882 KB) View Article

  4. No Access

    Article

    Ferroptosis and Its Role in Diverse Brain Diseases

    Ferroptosis is a recently identified, iron-regulated, non-apoptotic form of cell death. It is characterized by cellular accumulation of lipid reactive oxygen species that ultimately leads to oxidative stress a...

    Abigail Weiland, Yamei Wang, Weihua Wu, ** Lan, **aoning Han… in Molecular Neurobiology (2019)